SCHEMBL2019640

SCHEMBL2019640

CC(=O)Nc1cccc(Nc2ncnc3[nH]cc(C(=O)c4cccc(F)c4)c23)c1

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
BTK Q06187 11/20 0.48
BRAF P15056 4/20 0.48
TNNI3K Q59H18 4/20 0.48
ABCG2 Q9UNQ0 1/20 0.47
PTK2 Q05397 1/20 0.45
ABL1 P00519 1/20 0.45
EGFR P00533 1/20 0.45
ABL2 P42684 1/20 0.45
ROCK2 O75116 1/20 0.45
LIMK1 P53667 1/20 0.45
JAK3 P52333 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2019802 0.90 ABCG2 (0.54) BTKBRAFTNNI3KABCG2EGFR
SCHEMBL15381969 0.89 BTK (0.50) BTKBRAFTNNI3KABCG2ABL1
SCHEMBL2016446 0.87 BTK (0.51) BTKBRAFTNNI3KABL1EGFR
SCHEMBL2021223 0.82 BTK (0.60) BTKABCG2
SCHEMBL2016793 0.82 BTK (0.49) BTKBRAFTNNI3K
SCHEMBL13570611 0.82 BTK (0.55) BTKBRAFTNNI3KEGFRROCK2
SCHEMBL2019413 0.81 BTK (0.54) BTKBRAFTNNI3KROCK2LIMK1
SCHEMBL12490856 0.81 BTK (0.59) BTKEGFR
SCHEMBL2020584 0.81 ABCG2 (0.55) BTKABCG2PTK2EGFRJAK3
SCHEMBL2022991 0.81 BTK (0.56) BTKBRAFEGFRROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
CN-102892768-A Substituted pyrrolo-aminopyrimidine compounds ARQULE INC 2013-01-23 CN disclosed
EP-2519525-A2 SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-11-07 EP disclosed
WO-2011082273-A2 SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
WO-2011082273-A2 SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds DPYD, TYMP, DHFR BTK 1600/4885BRAF 470/4885TNNI3K 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.